A big step forward in cancer therapy has been slowed by layoffs and new restrictions at the National Institutes of Health, where it was developed.

Pheast Therapeutics has treated the first patient in a phase 1 trial of PHST001, a novel macrophage checkpoint inhibitor for advanced solid tumors.

Researchers have unlocked a powerful new way to fight solid tumors using smart immune cells that stay active longer and hit ...

Researchers in South Korea have proposed a novel cancer immunotherapy approach that could complement existing CAR-T (Chimeric ...

Patients with solid tumor malignancies had better survival after ICI therapy if they were obese than if they had a normal BMI.

Carlsbad, California Monday, April 14, 2025, 10:00 Hrs [IST] ...

Iovance's Amtagvi is the first TIL therapy approved by the U.S. Food and Drug Administration (FDA). Its first approved indication is for advanced melanoma. Amtagvi is off to a great start after its ...

Vividion Therapeutics, Inc. (Vividion) today announced that the first patient has been dosed in a Phase I clinical trial ...

The GI Cancers Symposium revealed new therapies for specific cancer subsets and progress in chimeric antigen receptor T-cell ...

NIH researchers discovered that a new form of personalized cancer immunotherapy dramatically improved the treatment’s ...

A phase 1 open-label trial is underway, evaluating the safety and efficacy of CT-95 in patients with mesothelin-expressing ...